Elite Pharmaceuticals, Inc.
ELTP
$0.37
$0.00-0.62%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 77.13% | 100.18% | 72.67% | 58.70% | 48.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.13% | 100.18% | 72.67% | 58.70% | 48.42% |
| Cost of Revenue | 67.99% | 75.43% | 47.89% | 28.18% | 45.23% |
| Gross Profit | 87.16% | 131.47% | 103.30% | 95.60% | 52.09% |
| SG&A Expenses | 92.57% | 28.61% | 47.83% | 39.41% | 26.34% |
| Depreciation & Amortization | -8.32% | -4.31% | 3.94% | 12.20% | 22.36% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.40% | 52.95% | 39.89% | 24.37% | 37.10% |
| Operating Income | 135.62% | 324.49% | 199.57% | 199.13% | 96.54% |
| Income Before Tax | 109,148.75% | 418.69% | 450.63% | -10,483.69% | -111.25% |
| Income Tax Expenses | 180.15% | 1,702.49% | 2,658.43% | 147.79% | 121.70% |
| Earnings from Continuing Operations | 1,140.02% | 341.34% | 317.96% | -155.23% | -121.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1,140.02% | 341.34% | 317.96% | -155.23% | -121.46% |
| EBIT | 135.62% | 324.49% | 199.57% | 199.13% | 96.54% |
| EBITDA | 125.00% | 285.41% | 180.81% | 180.38% | 88.33% |
| EPS Basic | 1,142.50% | 343.98% | 328.07% | -152.33% | -120.20% |
| Normalized Basic EPS | 3,622.22% | 427.72% | 396.00% | 109.09% | 212.50% |
| EPS Diluted | 380.00% | 186.87% | 112.36% | -228.07% | -133.61% |
| Normalized Diluted EPS | 3,355.56% | 415.84% | 386.00% | 109.09% | 212.50% |
| Average Basic Shares Outstanding | 0.42% | 1.39% | 2.56% | 3.82% | 5.21% |
| Average Diluted Shares Outstanding | 6.04% | 4.05% | 3.41% | 2.86% | 4.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |